Clinical Trial Update: A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating neoadjuvant mFOLFOX7 plus cetuximab to assess surgical conversion rate in unresectable colorectal cancer with liver-restricted metastas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• mFOLFOX7 (modified FOLFOX7)

Snippet

Sponsor: NSABP Foundation Inc | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-09-14